NCT06169644 The Psychological Impact of GTN on Women Who Have Completed Chemotherapy Treatment
| NCT ID | NCT06169644 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sheffield Teaching Hospitals NHS Foundation Trust |
| Condition | Gestational Trophoblastic Neoplasia |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-05-15 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2024-05-15 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A cross-sectional retrospective study of a sample of 20 women who completed single agent or multi agent chemotherapy: between 6 weeks and 24 months post treatment involving a semi structured telephone interview. A patient sample of 20 is proposed for the study. These are all the patients who meet the inclusion criteria below and are thus eligible for the study. These patients will be contacted via telephone by the principal investigator to inform them of the study and invite participation. A proposed sample size of 20 is sufficient to generate data to address the central questions and furthermore, this sample size is adequate because the intention is to gain insight into the experiences of patients' perceptions about their psychological experiences. Objectives: * Gaining insight into the emotional impact of GTN post treatment * Ascertaining if health professionals are providing adequate psychological support * Identifying sources of support that patients accessed post completion of treatment * Identifying potential areas of improvement in the follow up support for future patients Criteria for inclusion: * Treated with chemotherapy for a GTN diagnosis * Completed treatment between 6 weeks and 24 months * Are able to provide informed consent * Have no cognitive impairment as judged by the treating clinician Criteria for exclusion * Treatment received less than 6 weeks ago * Treatment received more than 24 months ago * Non-English speaking Outcome measures are not appropriate in this qualitative study. However outputs from this study include increasing knowledge and insight into: * patients' experiences of their psychological experiences post chemotherapy * patients' perspective of the support received after their treatment * potential areas of improvements in care
Eligibility Criteria
Inclusion Criteria: * Treated with chemotherapy for a GTN diagnosis * Completed treatment between 6 weeks and 24 months * Are able to provide informed consent * Have no cognitive impairment as judged by the treating clinician Exclusion Criteria: * Treatment received less than 6 weeks ago * Treatment received more than 24 months ago * Non-English speaking
Contact & Investigator
Kamaljit Singh
PRINCIPAL INVESTIGATOR
Nurse Consultant
Frequently Asked Questions
Who can join the NCT06169644 clinical trial?
This trial is open to female participants only, aged 16 Years or older, up to 55 Years, studying Gestational Trophoblastic Neoplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06169644 currently recruiting?
Yes, NCT06169644 is actively recruiting participants. Contact the research team at kamaljitsingh@nhs.net for enrollment information.
Where is the NCT06169644 trial being conducted?
This trial is being conducted at Sheffield, United Kingdom.
Who is sponsoring the NCT06169644 clinical trial?
NCT06169644 is sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. The principal investigator is Kamaljit Singh at Nurse Consultant. The trial plans to enroll 20 participants.